Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
Five-year PFS results show advantage for niraparib maintenance in patients with advanced ovarian cancer, with no OS benefit
Pembrolizumab plus concurrent chemoradiotherapy extends survival in locally advanced cervical cancer